Tiankang: The preliminary results of the Phase II clinical trial of CKBA ointment for vitiligo have achieved the expected goals.

Tiankang announcement, the phase II clinical trial data of the innovative drug CKBA ointment for vitiligo independently developed by its holding subsidiary Bochuangyuan has been compiled and the blinding has been unveiled. Preliminary results show that CKBA ointment has shown positive efficacy and good safety in non-segmental vitiligo patients, supporting the continuation of phase III confirmatory clinical trials. The proportion of subjects in the high-dose group CKBA ointment 1.5% BID dose group achieving F-VASI 50 and F-VASI 25 on the face and neck vitiligo scoring index was better than the solvent group, with 36% of patients showing improvement and varying degrees of repigmentation. The main adverse events in the trial were itching and erythema, both grade 1-2, and no serious adverse events occurred.